推动中国AML精准诊疗规范化进程 首部《吉瑞替尼治疗伴FLT3突变成年人急性髓系白血病临床应用指导原则（2025年版）》发布

Group 1 - The first clinical application guidelines for the use of Gilteritinib in adults with FLT3-mutated acute myeloid leukemia (AML) have been officially released, aiming to provide authoritative clinical guidance for standardized diagnosis and treatment [1][2] - The guidelines were developed by the Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, integrating global evidence and Chinese clinical practices, covering key areas such as FLT3 mutation testing, Gilteritinib treatment regimens, minimal residual disease (MRD) monitoring, and adverse reaction management [1][2] - The guidelines emphasize the importance of high-sensitivity MRD dynamic monitoring as a core method for guiding post-transplant maintenance therapy and individualized interventions, marking a shift towards precision medicine in the treatment of FLT3-mutated AML [2] Group 2 - Gilteritinib, a second-generation type I FLT3 inhibitor, has been approved in China for the treatment of relapsed or refractory FLT3-mutated AML since 2021, and has accumulated substantial evidence in new diagnosis and post-transplant maintenance therapy [2] - The release of these guidelines is expected to enhance the long-term survival rates of patients through standardized testing and precise medication, contributing to the high-quality development of the blood cancer prevention and treatment system in China [2]